This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout. This is a multi-center, double-blind, randomized, parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of efficacy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
234
Novartis
Nuremberg, Germany
For Site Information, contact Novartis Pharma AG
Basel, CH, Switzerland
Pain intensity in the study joint over days 2 to 5 approximately 4h after the first daily dose
Safety and tolerability profile
Pain intensity in the study joint over the entire treatment period
Patient's and Physician's global assessment of response to therapy
Physician's assessment of tenderness and swelling of study joint
C-reactive protein level
Proportion of patients who discontinued treatment because of a lack of efficacy
Usage of rescue medication
SF-36 and EQ-5D
Physician's assessment of erythema of study joint
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.